Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$7.71 -4.0%	$5.56	$3.76 ▼ $46.80	$49.10M	2.69	208,757 shs	136,904 shs
DMAC DiaMedica Therapeutics	$3.65 -6.4%	$3.95	$2.14 ▼ $6.82	$156.52M	1.23	85,721 shs	112,709 shs
FATE Fate Therapeutics	$1.28 -8.9%	$1.20	$0.66 ▼ $5.92	$146.12M	2.23	2.25 million shs	2.43 million shs
INMB INmune Bio	$7.70 -2.8%	$7.53	$4.32 ▼ $10.50	$176.98M	1.55	288,359 shs	593,330 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+7.08%	+32.93%	-32.60%	-39.53%
DMAC DiaMedica Therapeutics	0.00%	-11.84%	-10.32%	-36.74%	+45.42%
FATE Fate Therapeutics	0.00%	-20.31%	+26.24%	+35.42%	-66.18%
INMB INmune Bio	0.00%	+1.05%	+5.62%	-3.14%	-12.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.4254 of 5 stars	3.5	4.0	4.8	2.7	1.7	0.6
DMAC DiaMedica Therapeutics	1.3053 of 5 stars	3.5	1.0	0.0	2.5	0.0	0.0
FATE Fate Therapeutics	4.0809 of 5 stars	3.1	3.0	4.7	2.6	1.7	0.6
INMB INmune Bio	1.886 of 5 stars	3.6	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$70.00	807.91% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	119.18% Upside
FATE Fate Therapeutics	2.22	Hold	$4.14	224.93% Upside
INMB INmune Bio	3.17	Buy	$22.80	196.10% Upside

Current Analyst Ratings Breakdown

Latest ALGS, INMB, DMAC, and FATE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/31/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
3/19/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.27M	14.42	N/A	N/A	$30.65 per share	0.25
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
FATE Fate Therapeutics	$13.34M	10.96	N/A	N/A	$3.74 per share	0.34
INMB INmune Bio	$50K	3,539.54	N/A	N/A	$2.07 per share	3.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$87.68M	-$17.51	N/A	N/A	N/A	-1,283.19%	-114.34%	-64.58%	8/5/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$19.38M	-$0.64	N/A	N/A	N/A	N/A	-43.67%	-40.81%	8/6/2025 (Estimated)
FATE Fate Therapeutics	-$160.93M	-$1.49	N/A	N/A	N/A	-1,325.43%	-45.88%	-33.95%	8/12/2025 (Estimated)
INMB INmune Bio	-$30.01M	-$1.93	N/A	N/A	N/A	N/A	-117.48%	-78.96%	7/30/2025 (Estimated)

Latest ALGS, INMB, DMAC, and FATE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	ALGS Aligos Therapeutics	-$2.80	-$2.11	+$0.69	-$2.11	$0.33 million	$0.31 million
3/27/2025	Q4 2024	INMB INmune Bio	-$0.54	-$0.40	+$0.14	-$0.40	N/A	N/A
3/17/2025	Q4 2024	DMAC DiaMedica Therapeutics	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	3.81	3.81
DMAC DiaMedica Therapeutics	N/A	11.81	11.81
FATE Fate Therapeutics	N/A	8.29	8.29
INMB INmune Bio	N/A	2.59	2.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
DMAC DiaMedica Therapeutics	10.12%
FATE Fate Therapeutics	97.54%
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
DMAC DiaMedica Therapeutics	7.30%
FATE Fate Therapeutics	5.51%
INMB INmune Bio	35.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.11 million	3.27 million	No Data
DMAC DiaMedica Therapeutics	20	42.88 million	39.68 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.20 million	Optionable
INMB INmune Bio	10	22.98 million	14.37 million	Optionable

ALGS, INMB, DMAC, and FATE Headlines

Recent News About These Companies

INmune Bio, Inc. Collaborates on Study Showing XPro™ Treatment Reduces Alzheimer’s-like Pathology After Traumatic Brain Injury in Mice

June 12 at 7:01 AM | nasdaq.com

INmune Bio, Inc. (NASDAQ:INMB) Shares Bought by Two Sigma Investments LP

June 11, 2025 | marketbeat.com

Millennium Management LLC Boosts Stake in INmune Bio, Inc. (NASDAQ:INMB)

June 4, 2025 | marketbeat.com

INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

May 15, 2025 | seekingalpha.com

INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

INmune Bio appoints new accounting firm

May 9, 2025 | investing.com

INmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 9, 2025 | finanznachrichten.de

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 8, 2025 | globenewswire.com

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

May 5, 2025 | globenewswire.com

INmune Bio to receive US patent for next-generation mesenchymal stromal cell product, CORDStrom

April 19, 2025 | pharmabiz.com

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

April 16, 2025 | markets.businessinsider.com

INmune Bio receives favorable patentability opinion for CORDStrom platform

April 16, 2025 | markets.businessinsider.com

INmune Bio partners with Cell, Gene Therapy Catapult to scale up CORDStrom

April 14, 2025 | markets.businessinsider.com

INmune Bio Partners with Cell and Gene Therapy Catapult

April 14, 2025 | msn.com

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

April 14, 2025 | globenewswire.com

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

April 1, 2025 | markets.businessinsider.com

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript

March 29, 2025 | msn.com

INmune Bio, Inc.: INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

March 29, 2025 | finanznachrichten.de

Scotiabank Remains a Buy on Inmune Bio (INMB)

March 29, 2025 | markets.businessinsider.com

Alliance Global Partners Reaffirms Their Buy Rating on Inmune Bio (INMB)

March 29, 2025 | markets.businessinsider.com

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

March 27, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, INMB, DMAC, and FATE Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$7.71 -0.32 (-3.99%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.98 +0.27 (+3.49%)

As of 06/13/2025 07:25 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

DiaMedica Therapeutics NASDAQ:DMAC

$3.66 -0.24 (-6.15%)

As of 06/13/2025 04:00 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Fate Therapeutics NASDAQ:FATE

$1.27 -0.13 (-8.93%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.28 +0.00 (+0.08%)

As of 06/13/2025 07:55 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

INmune Bio NASDAQ:INMB

$7.70 -0.22 (-2.78%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.70 0.00 (0.00%)

As of 06/13/2025 06:25 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time